Corte, Tamera J.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 1,444

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 629

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Biomarker signatures for progressive idiopathic pulmonary fibrosis

Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 86

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry

Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., et al. (2018) · BMC Pulmonary Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 77

Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 70

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial

West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., et al. (2023) · Thorax

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 67

Metformin does not affect clinically relevant outcomes in patients with idiopathic pulmonary fibrosis

Spagnolo, P., Kreuter, M., Maher, T. M., Wuyts, W., Bonella, F., Corte, T. J., Kopf, S., Weycker, D., Kirchgaessler, K.-U., & Ryerson, C. J. (2018) · Respiration

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 61

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 59

Safety and Efficacy of Inhaled Pirfenidone (AP01) in the Atlas Open-label Extension Study

Wilsher, M. L., Woodhead, F. A., Nair, D., Bao, H., Lazarus, H. M., & Corte, T. J. (2024) · B48. NEW TREATMENTS IN DIFFUSE PARENCHYMAL LUNG DISEASE

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisInhalation and Respiratory Drug Delivery

Cited by 1

Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis

Kolb, M., Corte, T. J., Feldman, J., Nathan, S. D., Reisner, C., Nair, D., Woodhead, F., Lazarus, H., & Conoscenti, C. (2025) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisInhalation and Respiratory Drug Delivery

Cited by 1